Renaissance Technologies LLC Has $2.02 Million Stock Holdings in Certara, Inc. $CERT

Renaissance Technologies LLC raised its holdings in Certara, Inc. (NASDAQ:CERT) by 1,097.6% during the first quarter, Holdings Channel reports. The institutional investor owned 354,500 shares of the company’s stock after buying an additional 324,900 shares during the quarter. Renaissance Technologies LLC’s holdings in Certara were worth $2,021,000 as of its most recent SEC filing.

Other hedge funds have also recently made changes to their positions in the company. Granite Investment Partners LLC acquired a new stake in shares of Certara in the 1st quarter worth about $2,130,000. UBS Group AG boosted its stake in Certara by 50.7% during the 4th quarter. UBS Group AG now owns 2,489,603 shares of the company’s stock valued at $21,933,000 after purchasing an additional 837,648 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Certara by 2.1% during the 1st quarter. Dimensional Fund Advisors LP now owns 8,562,508 shares of the company’s stock worth $48,806,000 after purchasing an additional 175,024 shares in the last quarter. Jefferies Financial Group Inc. bought a new stake in Certara during the 4th quarter worth approximately $26,706,000. Finally, Y Intercept Hong Kong Ltd purchased a new stake in shares of Certara in the first quarter worth approximately $1,980,000. 73.96% of the stock is currently owned by institutional investors and hedge funds.

Certara Stock Up 0.7%

CERT stock opened at $8.13 on Wednesday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 2.55 and a current ratio of 2.55. The company has a market capitalization of $1.24 billion, a price-to-earnings ratio of -18.07 and a beta of 1.44. Certara, Inc. has a fifty-two week low of $4.45 and a fifty-two week high of $13.88. The stock has a fifty day moving average of $6.65 and a 200-day moving average of $6.51.

Certara (NASDAQ:CERT) last announced its quarterly earnings data on Tuesday, August 4th. The company reported $0.08 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.09 by ($0.01). Certara had a negative net margin of 16.75% and a positive return on equity of 3.86%. The firm had revenue of $93.27 million during the quarter, compared to the consensus estimate of $98.09 million. During the same quarter in the prior year, the firm posted $0.07 earnings per share. The company’s revenue was down 10.8% on a year-over-year basis. As a group, equities research analysts predict that Certara, Inc. will post 0.24 earnings per share for the current year.

Analyst Ratings Changes

A number of research analysts have recently weighed in on CERT shares. BMO Capital Markets dropped their target price on Certara from $7.00 to $6.00 and set a “market perform” rating on the stock in a report on Tuesday, May 12th. Stephens decreased their price target on Certara from $10.00 to $9.00 and set an “overweight” rating for the company in a report on Tuesday, May 12th. Morgan Stanley lowered their price target on Certara from $11.00 to $10.00 and set an “equal weight” rating for the company in a research report on Tuesday, May 12th. Weiss Ratings upgraded Certara from a “sell (e+)” rating to a “sell (d)” rating in a research note on Wednesday, August 5th. Finally, Barclays lifted their price objective on shares of Certara from $6.50 to $7.50 and gave the stock an “equal weight” rating in a report on Wednesday, August 5th. One analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $8.28.

About Certara

Certara is a biosimulation software and services company that partners with pharmaceutical, biotechnology and medical device developers to accelerate drug discovery, development and regulatory approval. The company’s platform integrates quantitative pharmacology, real-world evidence, artificial intelligence and machine learning to model and simulate drug behavior across a range of therapeutic areas and patient populations. By applying these mechanistic and data-driven approaches, Certara helps its clients predict clinical outcomes, optimize dosing strategies and streamline decision-making throughout the product lifecycle.

The company’s offerings are divided into software tools and consulting services.